Form 4: Oric Pharmaceuticals CFO Sells Over 33,000 Shares Under Pre-Arranged Trading Plan

Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc., reported the sale of 33,500 shares of common stock in late June 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported the sale of common stock through multiple transactions.
• A total of 33,500 shares were sold across three separate transactions on June 23 and June 24, 2025.
• The sales on June 23, 2025, included 584 shares at $10.00 per share and 450 shares at $10.01 per share.
• On June 24, 2025, an additional 32,466 shares were sold at a weighted average price of $10.5045 per share, with prices ranging from $10.34 to $10.80.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan that Mr. Piscitelli adopted on December 30, 2024.
• Following these reported sales, Mr. Piscitelli's direct beneficial ownership in Oric Pharmaceuticals, Inc. stands at 68,317 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic trading, indicating a planned liquidity event rather than a reaction to new negative information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which indicates pre-scheduled transactions and reduces the perception of opportunistic insider trading, aligning with good corporate governance practices.

Negatives

• The Chief Financial Officer, Dominic Piscitelli, sold a significant number of shares (33,500 shares), which, despite being pre-planned, could be interpreted by some investors as a signal of reduced confidence or a desire for personal liquidity.

Risks

• Potential for negative investor sentiment due to insider selling, even if pre-planned, which could put downward pressure on the company's stock price.

Future Outlook

This document, an SEC Form 4, reports insider trading activity and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024."

Industry Context

This Form 4 filing is specific to Oric Pharmaceuticals, Inc. and its Chief Financial Officer's stock transactions. It does not provide information on broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the CFO's sale of shares differently; some may view it as a routine diversification or liquidity event under a pre-planned schedule, while others might interpret it as a signal of reduced confidence, potentially influencing stock price.

Key Dates

Recommendation

Keywords

Oric Pharmaceuticals, ORIC, Form 4, insider trading, stock sale, Rule 10b5-1, Dominic Piscitelli, CFO, beneficial ownership